You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrednicarbate
Accession NumberDB01130  (APRD01197)
TypeSmall Molecule
GroupsApproved
DescriptionPrednicarbate is a relatively new topical corticosteroid drug. It is similar in potency to hydrocortisone. It is used in the treatment of inflammatory skin diseases, such as atopic dermatitis. It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. The anti-inflammation action of corticosteroids is associated with the inhibition of the interleukin 1-alpha cytokine within keratinocytes. IL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness.
Structure
Thumb
SynonymsNot Available
External Identifiers
  • LAS-189961
  • LAS189961
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dermatopcream1 mg/gtopicalValeant Pharmaceuticals North America LLC1993-10-29Not applicableUs
Dermatopointment1 mg/gtopicalValeant Pharmaceuticals North America LLC2014-06-23Not applicableUs
Dermatop Emollient Creamcream0.1 %topicalValeant Canada Lp Valeant Canada S.E.C.2001-03-21Not applicableCanada
Dermatop Ointmentointment0.1 %topicalValeant Canada Lp Valeant Canada S.E.C.2001-03-21Not applicableCanada
Prednicarbatecream1 mg/gtopicalPrasco Laboratories2007-04-30Not applicableUs
Prednicarbatecream1 mg/gtopicalOceanside Pharmaceuticals1993-10-29Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Prednicarbatecream1 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2006-09-19Not applicableUs
Prednicarbateointment1 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2007-03-09Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Dermatop E EmollientNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV901LV1K7D
CAS number73771-04-7
WeightAverage: 488.577
Monoisotopic: 488.241018119
Chemical FormulaC27H36O8
InChI KeyFNPXMHRZILFCKX-KAJVQRHHSA-N
InChI
InChI=1S/C27H36O8/c1-5-22(31)34-15-21(30)27(35-24(32)33-6-2)12-10-19-18-8-7-16-13-17(28)9-11-25(16,3)23(18)20(29)14-26(19,27)4/h9,11,13,18-20,23,29H,5-8,10,12,14-15H2,1-4H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1
IUPAC Name
2-[(1S,2R,10S,11S,14R,15S,17S)-14-[(ethoxycarbonyl)oxy]-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-14-yl]-2-oxoethyl propanoate
SMILES
[H][C@@]12CC[C@](OC(=O)OCC)(C(=O)COC(=O)CC)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
Substituents
  • Progestogin-skeleton
  • Steroid ester
  • 20-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • 3-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Carbonic acid diester
  • Cyclic alcohol
  • Carbonic acid derivative
  • Ketone
  • Carboxylic acid ester
  • Secondary alcohol
  • Cyclic ketone
  • Carboxylic acid derivative
  • Monocarboxylic acid or derivatives
  • Organic oxygen compound
  • Carbonyl group
  • Hydrocarbon derivative
  • Alcohol
  • Organooxygen compound
  • Organic oxide
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
PharmacodynamicsCorticosteroids diffuse across cell membranes and complex with specific cytoplasmic receptors. These complexes then enter the cell nucleus, bind to DNA (chromatin), and stimulate transcription of messenger RNA (mRNA) and subsequent protein synthesis of various inhibitory enzymes responsible for the anti-inflammatory effects of topical corticosteroids. These anti-inflammatory effects include inhibition of early processes such as edema, fibrin deposition, capillary dilatation, movement of phagocytes into the area, and phagocytic activities. Later processes, such as capillary production, collagen deposition, and keloid formation also are inhibited by corticosteroids.
Mechanism of actionIn common with other topical corticosteroids, prednicarbate has anti-inflammatory, antipruritic, and vasoconstrictive properties. In general, the mechanism of the anti-inflammatory activity of topical steroids is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
Related Articles
AbsorptionAbsorbed systemically across the stratum corneum.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily in skin

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9958
Blood Brain Barrier+0.984
Caco-2 permeable-0.571
P-glycoprotein substrateSubstrate0.7928
P-glycoprotein inhibitor IInhibitor0.8358
P-glycoprotein inhibitor IINon-inhibitor0.6129
Renal organic cation transporterNon-inhibitor0.7659
CYP450 2C9 substrateNon-substrate0.8753
CYP450 2D6 substrateNon-substrate0.895
CYP450 3A4 substrateSubstrate0.7638
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9054
CYP450 2D6 inhibitorNon-inhibitor0.9032
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.841
Ames testNon AMES toxic0.9186
CarcinogenicityNon-carcinogens0.9164
BiodegradationNot ready biodegradable0.9757
Rat acute toxicity2.4426 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8758
hERG inhibition (predictor II)Non-inhibitor0.5989
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Creamtopical0.1 %
Ointmenttopical0.1 %
Creamtopical1 mg/g
Ointmenttopical1 mg/g
Prices
Unit descriptionCostUnit
Prednicarbate 0.1% Ointment 60 gm Tube76.74USD tube
Dermatop 0.1% Cream 60 gm Tube75.2USD tube
Dermatop 0.1% Ointment 60 gm Tube70.06USD tube
Prednicarbate 0.1% Cream 60 gm Tube59.03USD tube
Prednicarbate 0.1% Ointment 15 gm Tube37.31USD tube
Prednicarbate 0.1% Cream 15 gm Tube24.0USD tube
Dermatop 0.1% cream1.76USD g
Prednicarbate 0.1% cream1.41USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00562 mg/mLALOGPS
logP3.08ALOGPS
logP3.83ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)14.83ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area116.2 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity127.8 m3·mol-1ChemAxon
Polarizability52.43 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Gupta AK, Chow M: A review of prednicarbate (Dermatop). Skin Therapy Lett. 2004 Dec-2005 Jan;9(10):5-6, 9. [PubMed:15657633 ]
External Links
ATC CodesD07AC18
AHFS Codes
  • 84:06.00
  • 92:04.00*
PDB EntriesNot Available
FDA labelDownload (130 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with 1,10-Phenanthroline.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednicarbate.
AldesleukinPrednicarbate may decrease the antineoplastic activities of Aldesleukin.
Aluminum hydroxideThe bioavailability of Prednicarbate can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Prednicarbate can be decreased when combined with Aluminum phosphate.
AmbenoniumThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Ambenonium.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednicarbate.
AmiodaroneThe serum concentration of Prednicarbate can be increased when it is combined with Amiodarone.
Amphotericin BPrednicarbate may increase the hypokalemic activities of Amphotericin B.
AprepitantThe serum concentration of Prednicarbate can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Prednicarbate can be increased when it is combined with Atazanavir.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prednicarbate.
BazedoxifeneThe serum concentration of Prednicarbate can be increased when it is combined with Bazedoxifene.
BendroflumethiazidePrednicarbate may increase the hypokalemic activities of Bendroflumethiazide.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prednicarbate.
Bismuth SubcitrateThe bioavailability of Prednicarbate can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Prednicarbate can be increased when it is combined with Boceprevir.
BumetanidePrednicarbate may increase the hypokalemic activities of Bumetanide.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednicarbate.
Calcium carbonateThe bioavailability of Prednicarbate can be decreased when combined with Calcium carbonate.
CarbamazepineThe serum concentration of Prednicarbate can be decreased when it is combined with Carbamazepine.
CeritinibPrednicarbate may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Prednicarbate can be increased when it is combined with Ceritinib.
ChlorothiazidePrednicarbate may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Prednicarbate can be increased when it is combined with Chlorotrianisene.
ChlorthalidonePrednicarbate may increase the hypokalemic activities of Chlorthalidone.
CholestyramineCholestyramine can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ClarithromycinThe serum concentration of Prednicarbate can be increased when it is combined with Clarithromycin.
CobicistatThe serum concentration of Prednicarbate can be increased when it is combined with Cobicistat.
ColesevelamColesevelam can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Prednicarbate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Conjugated Equine EstrogensThe serum concentration of Prednicarbate can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednicarbate.
CoumaphosThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Coumaphos.
DarunavirThe serum concentration of Prednicarbate can be increased when it is combined with Darunavir.
DecamethoniumThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Decamethonium.
DeferasiroxThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Deferasirox.
DemecariumThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Demecarium.
DichlorvosThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Dichlorvos.
DienestrolThe serum concentration of Prednicarbate can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Prednicarbate can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednicarbate.
DihydrotestosteronePrednicarbate may increase the fluid retaining activities of Dihydrotestosterone.
DonepezilThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Donepezil.
EchothiophateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Edrophonium.
EnzalutamideThe serum concentration of Prednicarbate can be decreased when it is combined with Enzalutamide.
EstradiolThe serum concentration of Prednicarbate can be increased when it is combined with Estradiol.
EstriolThe serum concentration of Prednicarbate can be increased when it is combined with Estriol.
EstroneThe serum concentration of Prednicarbate can be increased when it is combined with Estrone.
Etacrynic acidPrednicarbate may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Prednicarbate can be increased when it is combined with Ethinyl Estradiol.
FenthionThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Fenthion.
FluoxymesteronePrednicarbate may increase the fluid retaining activities of Fluoxymesterone.
FosaprepitantThe serum concentration of Prednicarbate can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Prednicarbate can be decreased when it is combined with Fosphenytoin.
FurosemidePrednicarbate may increase the hypokalemic activities of Furosemide.
GalantamineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Gallamine Triethiodide.
GenisteinThe serum concentration of Prednicarbate can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Ginkgo biloba.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prednicarbate.
HexestrolThe serum concentration of Prednicarbate can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednicarbate.
HydrochlorothiazidePrednicarbate may increase the hypokalemic activities of Hydrochlorothiazide.
HydroflumethiazidePrednicarbate may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Prednicarbate can be increased when it is combined with Idelalisib.
IndacaterolIndacaterol may increase the hypokalemic activities of Prednicarbate.
IndapamidePrednicarbate may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Prednicarbate can be increased when it is combined with Indinavir.
IsoflurophateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prednicarbate.
ItraconazoleThe serum concentration of Prednicarbate can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Prednicarbate can be increased when it is combined with Ketoconazole.
LopinavirThe serum concentration of Prednicarbate can be increased when it is combined with Lopinavir.
MagaldrateThe bioavailability of Prednicarbate can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Prednicarbate can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Prednicarbate can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Prednicarbate can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Malathion.
MefloquineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Mefloquine.
MemantineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Memantine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednicarbate.
MestranolThe serum concentration of Prednicarbate can be increased when it is combined with Mestranol.
MethyclothiazidePrednicarbate may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteronePrednicarbate may increase the fluid retaining activities of Methyltestosterone.
MetolazonePrednicarbate may increase the hypokalemic activities of Metolazone.
MifepristoneThe therapeutic efficacy of Prednicarbate can be decreased when used in combination with Mifepristone.
MinaprineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Minaprine.
MitotaneThe serum concentration of Prednicarbate can be decreased when it is combined with Mitotane.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Prednicarbate.
NefazodoneThe serum concentration of Prednicarbate can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Prednicarbate can be increased when it is combined with Nelfinavir.
NeostigmineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Neostigmine.
NevirapineThe serum concentration of Prednicarbate can be decreased when it is combined with Nevirapine.
NicorandilThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Nicorandil.
OxandrolonePrednicarbate may increase the fluid retaining activities of Oxandrolone.
OxymetholonePrednicarbate may increase the fluid retaining activities of Oxymetholone.
PentobarbitalThe serum concentration of Prednicarbate can be decreased when it is combined with Pentobarbital.
PhenobarbitalThe serum concentration of Prednicarbate can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prednicarbate.
PhenytoinThe serum concentration of Prednicarbate can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Physostigmine.
PiretanidePrednicarbate may increase the hypokalemic activities of Piretanide.
Polyestradiol phosphateThe serum concentration of Prednicarbate can be increased when it is combined with Polyestradiol phosphate.
PolythiazidePrednicarbate may increase the hypokalemic activities of Polythiazide.
PosaconazoleThe serum concentration of Prednicarbate can be increased when it is combined with Posaconazole.
PrimidoneThe serum concentration of Prednicarbate can be decreased when it is combined with Primidone.
PyridostigmineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Pyridostigmine.
QuinestrolThe serum concentration of Prednicarbate can be increased when it is combined with Quinestrol.
QuinethazonePrednicarbate may increase the hypokalemic activities of Quinethazone.
Rabies vaccineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rabies vaccine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Prednicarbate.
RifabutinThe serum concentration of Prednicarbate can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Prednicarbate can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Prednicarbate can be decreased when it is combined with Rifapentine.
RitonavirThe serum concentration of Prednicarbate can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Rivastigmine.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednicarbate.
SaquinavirThe serum concentration of Prednicarbate can be increased when it is combined with Saquinavir.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Prednicarbate.
StanozololPrednicarbate may increase the fluid retaining activities of Stanozolol.
Synthetic Conjugated Estrogens, AThe serum concentration of Prednicarbate can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Prednicarbate can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Tacrine.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prednicarbate.
TelaprevirThe serum concentration of Prednicarbate can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Prednicarbate can be increased when it is combined with Telithromycin.
TestosteronePrednicarbate may increase the fluid retaining activities of Testosterone.
TiboloneThe serum concentration of Prednicarbate can be increased when it is combined with Tibolone.
TorasemidePrednicarbate may increase the hypokalemic activities of Torasemide.
TrichlorfonThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Trichlorfon.
TrichlormethiazidePrednicarbate may increase the hypokalemic activities of Trichlormethiazide.
TubocurarineThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Tubocurarine.
VoriconazoleThe serum concentration of Prednicarbate can be increased when it is combined with Voriconazole.
WarfarinPrednicarbate may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Prednicarbate can be increased when it is combined with Zeranol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [PubMed:2879901 ]
  2. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [PubMed:19482847 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23